Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints

Controlled Clinical Trials

Volumn 25, Issue 2, 2004, Pages 168-177

  Capra, William B ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Classic randomized trial; Discontinuation trial; Hazard ratio; Phase II trials; Simulations; Weibull distribution

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXPERIMENTAL DESIGN; MATHEMATICAL ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIMULATION;

COMPUTER SIMULATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 1542351250     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2003.11.005     Document Type: Article

References (7)

1. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 10:1989;1-10.
2. Schaid D.J., Ingle J.N., Wieand S., Ahmann D.L. A design for phase II testing of anticancer agents within a phase III clinical trial. Control. Clin. Trials. 9:1988;107-118.
3. Chang M.N., Shuster J., Kepner J.L. Group sequential designs for phase II trials with historical controls. Control. Clin. Trials. 20:1999;353-364.
4. Friedman L.M., Furberg C.D., DeMets D.L. Fundamentals of Clinical Trials. third ed:1998;Springer, New York.
5. Kopec J.A., Abrahamowicz M., Esdaile J.M. Randomized discontinuation trials: utility and efficiency. J. Clin. Epidemiol. 46:1993;959-971.
6. Rosner G.L., Stadler W., Ratain M.J. Randomized discontinuation design: application to cytostatic antineoplastic agents. J. Clin. Oncol. 20(22):2002;4478-4484.
7. Leber P.D., Davis C.S. Threats to the validity of clinical trials employing discontinuation strategies for sample selection. Control. Clin. Trials. 19:1998;178-187.